查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771558

Zilvisc 市场规模、份额和趋势分析报告：按适应症、分销管道、地区和细分市场预测，2025-2030 年

Zilbrysq Market Size, Share & Trends Analysis Report By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Zilvisc（Zilcoplan）市场成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球 Zilvisc（Zilcoplan）市场规模预计到 2030 年将达到 6.7958 亿美元，预测期内的复合年增长率为 28.39%。

UCB 的First-in-Class自主给药皮下补体 C5 抑制剂 Zilbrysq 正在迅速重新定义全身型重症肌无力 (gMG) 的治疗模式。该药物已在美国、欧盟、日本、加拿大和韩国核准，其独特的给药模式和标靶作用机制使其成为罕见自体免疫神经肌肉疾病领域的宝贵疗法。

一个重要的驱动因素是基于机制的标靶治疗日益受到重视，尤其是对于皮质类固醇、静脉注射免疫球蛋白 (IVIg) 或血浆置换治疗效果不佳的鉅细胞性重症肌无力 (MG) 患者。 Zilvisc 能够选择性抑制终末补体激活，为临床医生提供精准干预，符合强调免疫特异性和长期安全性的现代治疗流程。此外，其每日一次的皮下给药配方打破了传统的医院依赖模式，实现了护理的分散化，并支持门诊和家庭环境中的长期疾病控制。这不仅提高了患者的依从性，还降低了输液相关成本，这对支付方来说是一个日益重要的考虑因素。 SC C5 缺乏直接竞争对手，进一步巩固了其商业性定位。此外，罕见疾病政策框架，例如对罕见疾病的优先治疗、加速核准以及主要市场的报销优先，正在加速药物的可及性和处方医生的接受度。这些动态，加上可预测的治疗人群和较低的治疗重迭，继续增强 Zilvisc 在 MG 治疗领域的策略价值。

Zilcoplan 选择性抑制补体成分 5 (C5) 的裂解，从而抑制膜攻击复合物 (C5b-9) 的形成，该复合物在乙酰胆碱受体 (AChR) 抗体阳性的巨噬细胞肌球蛋白 (gMG) 的神经肌肉接头功能障碍中起着核心作用。与传统的免疫抑制剂和生物製药的静脉注射不同，Zilvisc 以每日一次皮下注射的方式给药，使患者能够在家中自行给药。这显着减轻了治疗负担，并提高了长期依从性，尤其适用于从住院输液治疗过渡的患者。

截至2024年，Zirbisc已占据gMG适应症的100%份额，由于PNH、ALS和IMNM的临床计画已策略性终止，因此并未积极开发其他适应症。然而，其强大的疗效、便捷的皮下给药以及直至2030年的孤儿药专营权，使其拥有巨大的商业性护城河，并在核准人群中拥有可持续收益的潜力。

到2024年，专科药局的配药量将占到70%以上，这反映了对病患教育、遵从性监测和低温运输物流的需求。医院药房将继续在启动和支持新诊断病例和复杂病例的治疗方面发挥作用。同时，家庭医疗保健提供者是成长最快的分销领域，这得益于对分散式照护和改善家庭治疗基础设施的需求不断增长。

2023年10月，美国FDA核准了Zilvisc，该批准基于关键的RAISE研究，该研究表明，与安慰剂相比，Zilvisc在MG-ADL和QMG评分方面具有统计学显着改善。随后，该药物于2023年12月获得欧盟委员会核准，并在英国（2024年1月）、加拿大（2024年7月）和韩国（2024年11月）获得批准。此外，2024年5月检验的一项为期60週的扩展研究（RAISE-XT）核准了该药物在治疗遗传性肌强直（gMG）方面的长期安全性和持续临床效用。

此外，2024年11月宣布的一项人体因素检验研究证实，Zilvisc预填充式注射器易于患者、看护者和医护人员使用，进一步增强了其居家适用性，并符合以患者为中心的护理模式。随着全球精准医疗需求的成长，UCB正投资拓展亚太、拉丁美洲和中东地区的市场。公司策略重点在于供应链扩充性、真实世界临床数据产生和数位化依从性平台，预计将增强全球扩张和医疗服务的连续性。

Zilvisc 的商业性成功反映了整个行业正转向自主给药、针对特异性机制的生技药品，这些生物製剂无需住院即可提供持久的疾病控制。凭藉强大的临床基础和 SC补体抑制剂领域有限的直接竞争，Zilcoplan 预计将推动患者预后和生活品质的显着改善，并继续成为重组疾病领域的市场领导。

Zilvisc（Zilcoplan）市场报告重点

  • 整体重症肌无力 (gMG) 将在 2024 年继续占据市场主导地位，占 100% 的市场占有率。抗乙酰胆碱受体 (AChR) 抗体阳性患者的高盛行率，加上 Zilcoplan 作为补体 C5 抑制剂的标靶作用机制，推动了该药物的强劲应用。良好的临床试验结果、孤儿药专营权以及被纳入主要市场的最新治疗指南，加速了该药物的采用，尤其是在从传统免疫抑制剂和输液疗法过渡的患者中。
  • 按销售管道管道划分，专科药房占最大市场份额，2024 年占 70.35%。这种优势归因于该药物属于高成本、稀有生物製药，需要低温运输物流、病患教育和长期依从性支持。专科药房在管理续药核对和福利验证方面也发挥关键作用，尤其是对于像 Zilcoplan 这样的自行给药疗法。
  • 预计到2024年，北美将以77.78%的市场份额引领Zirvisc市场，这得益于该药物的早期核准、处方医生对补体抑製剂的广泛接受以及遗传性肌强直性肌炎（gMG）的高诊断率。该地区成熟的专科药房网络以及支付方对高价孤儿药的强烈报销意愿，进一步支撑了其强劲的商业表现。来自美国和加拿大临床的真实世界证据预计将增强治疗的连续性并扩大处方医生群体。
  • UCB 继续引领全球市场，这得益于策略性法规申报、有针对性的医生教育以及对上市后资料产生的投资。该公司的长期成长策略以供应链扩充性、现实世界依从性支援和地理扩张为重点，尤其是在日本、加拿大和韩国等市场。 UCB 在补体介导的神经肌肉疾病领域的专业定位使其在补体替代疗法有限的市场中拥有竞争优势。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章 Zilvisc（Zilcoplan）市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章 Zilvisc（Zilcoplan）市场：适应症业务分析

  • 2024年及2030年指示市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 全身性重症肌无力（gMG）
  • 其他的

第五章 Zilvisc（Zilcoplan）市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 专业药房
  • 医院/机构药房
  • 家庭医疗保健提供者

第六章 Zilvisc（Zilcoplan）市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • UCB

第 8 章 结论

Product Code: GVR-4-68040-616-0

Zilbrysq (Zilucoplan) Market Growth & Trends:

The global zilbrysq (zilucoplan) market size is anticipated to reach USD 679.58 million by 2030 and is expected to expand at a CAGR of 28.39% during the forecast period, according to a new report by Grand View Research, Inc. Zilbrysq, a first-in-class self-administered subcutaneous complement C5 inhibitor developed by UCB, is rapidly redefining the treatment paradigm for generalized myasthenia gravis (gMG). Approved in the U.S., EU, Japan, Canada, and South Korea, the therapy's unique delivery model and targeted mechanism have positioned it as a high-value therapeutic in the rare autoimmune neuromuscular segment.

A key driver is the growing prioritization of targeted, mechanism-based therapies in generalized myasthenia gravis (gMG), particularly for patients inadequately managed by corticosteroids, IVIg, or plasma exchange. Zilbrysq's ability to selectively inhibit terminal complement activation provides clinicians with a high-precision intervention that aligns with modern treatment algorithms focused on immunological specificity and long-term safety. In addition, its once-daily subcutaneous formulation disrupts the traditional hospital-dependent model, enabling therapy decentralization and supporting long-term disease control in outpatient and home settings. This has not only improved patient adherence but also reduced infusion-related costs-an increasingly important consideration for payers. The absence of direct SC C5 competitors further enhances its commercial positioning. Moreover, rare disease policy frameworks, including orphan drug incentives, expedited approvals, and national reimbursement prioritization in key markets, have accelerated both access and prescriber uptake. These dynamics, combined with a predictable treatment population and low therapeutic redundancy, continue to reinforce Zilbrysq's strategic value within the gMG treatment landscape.

Zilucoplan works by selectively inhibiting the cleavage of complement component 5 (C5), preventing formation of the membrane attack complex (C5b-9), which plays a central role in neuromuscular junction damage in AChR antibody-positive gMG. Unlike traditional immunosuppressants or IV biologics, Zilbrysq is administered via once-daily subcutaneous injection, allowing patients to self-manage their therapy at home. This significantly reduces treatment burden and improves long-term adherence, particularly among patients transitioning away from hospital-based IV infusions.

As of 2024, Zilbrysq holds 100% indication share for gMG, with no active development in additional indications following the strategic discontinuation of clinical programs in PNH, ALS, and IMNM. However, its strong efficacy profile, convenient SC delivery, and orphan drug exclusivity until 2030 provide a significant commercial moat and sustained revenue potential in its approved population.

Specialty pharmacies serve as the primary distribution channel, accounting for over 70% of dispensed volumes in 2024, reflecting the need for coordinated patient education, adherence monitoring, and cold-chain logistics. Hospital pharmacies continue to play a role in treatment initiation and support for newly diagnosed or complex cases. Meanwhile, home healthcare providers represent the fastest-growing distribution segment, driven by increasing demand for decentralized care and improved at-home treatment infrastructure.

In October 2023, the U.S. FDA approved Zilbrysq, supported by the pivotal RAISE study, which demonstrated statistically significant improvements in MG-ADL and QMG scores versus placebo. Subsequently, the European Commission approved the therapy in December 2023, followed by authorizations in the UK (January 2024), Canada (July 2024), and South Korea (November 2024). Moreover, a 60-week extension study (RAISE-XT) published in May 2024 validated the drug's long-term safety and durability of clinical benefit in gMG.

Further bolstering its real-world readiness, a human factors validation study published in November 2024 confirmed the usability of Zilbrysq's prefilled syringe for patients, caregivers, and healthcare professionals, reinforcing its at-home applicability and alignment with patient-centric care models. As demand for precision therapies rises globally, UCB invests in market expansion across Asia Pacific, Latin America, and the Middle East. Strategic emphasis on supply chain scalability, real-world data generation, and digital adherence platforms is expected to enhance global reach and continuity of care.

The commercial success of Zilbrysq reflects a broader industry shift toward self-administered, mechanism-specific biologics that offer durable disease control without the need for hospital-based delivery. With a strong clinical foundation and limited direct competition in the SC complement inhibitor class, Zilucoplan is poised to remain a market leader in gMG, driving meaningful improvements in patient outcomes and quality of life.

Zilbrysq (Zilucoplan) Market Report Highlights:

  • Generalized Myasthenia Gravis (gMG) remained the exclusive and leading indication in the market in 2024, accounting for 100% of the market share. The high prevalence of anti-acetylcholine receptor (AChR) antibody-positive patients, combined with Zilucoplan's targeted mechanism of action as a complement C5 inhibitor, has driven strong adoption. Favorable clinical trial outcomes, orphan drug exclusivity, and inclusion in updated treatment guidelines across key markets have accelerated uptake, particularly among patients transitioning from conventional immunosuppressants or IV therapies.
  • Specialty Pharmacies held the largest share of the distribution channel segment in the market in 2024, accounting for 70.35% of dispensed volumes. This dominance is attributed to the drug's classification as a high-cost orphan biologic requiring cold-chain logistics, patient education, and long-term adherence support-all core competencies of specialty pharmacy providers. Specialty pharmacies also play a crucial role in managing refill coordination and benefit verification, especially for self-administered therapies like Zilucoplan.
  • North America led the Zilbrysq market in 2024 with a share of 77.78%, supported by early regulatory approval, broad prescriber familiarity with complement inhibitors, and high diagnostic rates for gMG. The region's well-established specialty pharmacy networks and payer willingness to reimburse high-cost orphan drugs further support strong commercial performance. Real-world evidence from U.S. and Canadian clinical practice is expected to reinforce treatment persistence and expand the prescriber base.
  • UCB continues to lead the global market, backed by strategic regulatory filings, targeted physician education, and investments in post-marketing data generation. The company's long-term growth strategy underpins its emphasis on supply chain scalability, real-world adherence support, and regional expansion, especially in markets like Japan, Canada, and South Korea. UCB's focused positioning within complement-mediated neuromuscular disorders strengthens its competitive advantage in a market with limited direct SC-based alternatives.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Zilbrysq (Zilucoplan) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Patent Expiry Analysis
  • 3.6. Pricing Analysis

Chapter 4. Zilbrysq (Zilucoplan) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Generalized Myasthenia Gravis (gMG)
    • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Zilbrysq (Zilucoplan) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Specialty Pharmacies
    • 5.4.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Hospital/Institution-Based Pharmacies
    • 5.5.1. Hospital/Institution-Based Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Home Healthcare Providers
    • 5.6.1. Home Healthcare Providers Market, 2018 - 2030 (USD Million)

Chapter 6. Zilbrysq (Zilucoplan) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Zilbrysq (Zilucoplan) Market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 UK Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 France Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Italy Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Spain Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Norway Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 China Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Australia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 UAE Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Zilbrysq (Zilucoplan) Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and Distribution Channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Zilbrysq (Zilucoplan) Market dynamics
  • Fig. 12 Zilbrysq (Zilucoplan) Market: Porter's five forces analysis
  • Fig. 13 Zilbrysq (Zilucoplan) Market: PESTLE analysis
  • Fig. 14 Indication market, 2018 - 2030 (USD Million)
  • Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
  • Fig. 16 Others market, 2018 - 2030 (USD Million)
  • Fig. 17 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 18 Specialty Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 19 Hospital/Institution-Based Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 20 Home Healthcare Providers market, 2018 - 2030 (USD Million)
  • Fig. 21 Zilbrysq (Zilucoplan) Market revenue, by region
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework